Why the study?
Does the ARC-HBR criteria help in risk stratification for major bleeding and mortality in PAD patients undergoing EVT?
Does the ARC-HBR criteria help in risk stratification for major bleeding and mortality in PAD patients undergoing EVT?
The ARC-HBR criteria may be a useful tool for bleeding risk stratification in PAD patients undergoing endovascular therapy, given the high prevalence of high bleeding risk and its association with mortality.
Answers are grounded in this paper and cite their sources.
ARC-HBR criteria identify most PAD patients as high bleeding risk after EVT; hypothesis-generating for stratification, requiring prospective validation before practice change.
80.3% of PAD patients undergoing EVT for femoropopliteal artery lesions with contemporary drug-coated devices met the ARC-HBR criteria. Given that major bleeding events remarkably increased the risk of mortality after EVT, the ARC-HBR criteria might be helpful for the risk stratification of PAD patients who undergo EVT with contemporary DCD.
No takes yet. Share an insight, caveat, or question.
Tomoi et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: